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Abstract 
Curcumin is a promising anti-cancer drug but its applications in cancer therapy are limited due to its 
poor solubility, short half-life and low bioavailability. In this paper, we present a curcumin loaded 
magnetic silk fibroin core-shell nanoparticle system for sustained release of curcumin into breast 
cancer cells. Curcumin loaded magnetic silk fibroin core-shell nanoparticles were fabricated by a 
simple salting-out method using sodium phosphate with magnetic nanoparticles. The size, zeta 
potential, encapsulation/ loading efficiency and curcumin release rate were controlled and 
optimised by regulating silk fibroin concentration, pH value of the phosphate solution and curcumin 
usage. Curcumin loaded magnetic silk fibroin core-shell nanoparticles showed enhanced 
cytotoxicity and higher cellular uptake in the human Caucasian breast adenocarcinoma cell line 
(MDA-MB-231cells) evidenced by MTT and cellular uptake assays. In addition, silk fibroin 
nanoparticles and magnetic silk fibroin nanoparticles without curcumin loaded were used as 
controls. The particles prepared using sodium phosphate showed significantly smaller diameter 
(90-350 nm) compared with those prepared using potassium phosphate, which possess a diameter 
range of 500-1200 nm. These smaller particles are superior for biomedical applications since such 
size range is particularly desired for cell internalization. In addition, the magnetic cores inside the 
particles provide possibility of using an external magnet for cancer targeting. 
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1. Introduction 
Curcumin (CUR) is the main component of turmeric which is extracted from the root of Curcuma 
longa native to Southeast Asia 1. It is considered a pharmacologically safe drug 2 and has been 
widely used in medicine due to its anti-oxidant 3-5 anti-inflammatory 6-8 wound healing 9-10 and 
anti-bacterial 11-12 properties. Also, CUR has been widely used to fight against cisplatin-resistant 
cancer cells and decrease its unwanted side effects 13. Moreover, it has also been found that CUR 
may modulate markers of High-density lipoprotein (HDL) function and subsequently improve 
conditions in which HDL is dysfunctional 14. Recent research revealed that CUR also possess 
anti-cancer properties on multiple cell lines via its effects on the regulation of cellular growth and 
apoptosis 15-17 which makes it a promising drug for cancer therapy. However, due to its poor 
solubility in aqueous solution 18-19, short half-life in the body and low bioavailability after oral 
administration 20-22, the accumulation and uptake of CUR at the disease area by itself is very poor. 
Therefore, the applications of CUR as an anti-cancer drug have been significantly limited 19-21, 23. To 
overcome these obstacles, various strategies including the development of liposome 24, 
phospholipid 25, adjuvants 26 and nanoparticle carriers 27 for CUR delivery have been conducted. 
However, most of these drug delivery systems lack the ability of tumour targeting, which makes the 
accumulation of drugs at tumour sites limited. Thus, a drug delivery system which is capable of not 
only improving the availability, cell uptake and half-life of CUR, but can also deliver it to disease 
sites is desired. In this report, we present the fabrication of CUR loaded magnetic silk fibroin 
core-shell nanoparticles (CMSPs) for the delivery of CUR into breast cancer cells. 
Silk fibroin (SF) protein from cocoons of Bombyx mori is an FDA approved, natural derived material 
and has been widely used to form various biomaterials including SF gels, sponges and films for 
different medical applications 28. It has also been demonstrated that SF is an extremely promising 
material for drug delivery systems due to its excellent biocompatibility 29, tunable biodegradability 30 
and easy processing 28. An increasing number of strategies including capillary-microdot technique 31, 
desolvation method 32-35, supercritical fluid technologies 36 and salting-out method 37 have been 
developed to fabricate SF based nanoparticles that can load and release model drugs. For example, 
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Gupta et al. have fabricated CUR loaded SF nanoparticles (<100 nm) with the capillary-microdot 
technique 31. However, preparation of SF nanoparticles (SFPs) with this method is difficult to 
process and the yield is relatively low. Kundu et al. have prepared  SFPs (150 -170 nm) with the 
desolvation method by adding SF solutions into dimethyl sulfoxide (DMSO) 32. Nevertheless, the 
organic solvent residue in these SFPs is still difficult to avoid. Zhao et al. 36 have prepared smaller  
SFPs(~ 50 nm) using solution-enhanced dispersion by CO2. However, the processing of this 
method is complicated and the cost is high. Lammel et al. have developed a salting-out method for 
the preparation of SFPs (500 -1200 nm) by adding SF solution into potassium phosphate solutions 
37
. This method possesses several advantages such as low cost, simplicity and safe operation, 
avoiding the use of toxic solvents and easy to maintain protein activities. However, the size of SF 
particles prepared with this approach is relatively large, which means their circulation time in blood 
will be shorter and are more likely to be entrapped within the liver and spleen 38. 
Targeted drug delivery using magnetic carriers with an external magnetic field focused on the 
tumour areas has been reported as a promising strategy. This strategy possesses advantages such 
as visualize the targeting process, rapid targeting and potential of being heated in a magnetic field 
to promote drug release as well as avoiding complicated chemical modification of targeting ligands 
on the surface of nanocarriers39. Therefore, the combination of magnetic nanoparticles (MNPs) and 
SF become a promising strategy for targeted drug delivery. Recently, Shao and co-workers 
successfully prepared Doxorubicin (DOX) loaded magnetic silk fibroin nanoparticles (DMSPs) using 
the potassium phosphate salting-out method 40. The as-prepared DMSPs were proved capable of 
delivering the drug to the tumour site with the help of an external magnetic field. Nevertheless, 
targeted delivery of CUR using magnetic silk fibroin particles (MSPs), and the use of sodium 
phosphate to make smaller SFPs, to the best of our knowledge, has not yet been reported. It has 
been observed in our result that SFPs fabricated using sodium phosphate possess much smaller 
particle sizes (90 ± 300 nm) compared with those fabricated with potassium phosphate, which 
normally possess the size over 500 nm. Since the particle size and performance of SFPs produced 
using sodium phosphate is significantly different from those fabricated using potassium phosphate 
and the properties of these particles have not yet been studied. It is important to investigate the size, 
zeta potential, secondary structure, CUR loading/ release efficiency of SFPs and CMSPs prepared 
using sodium phosphate. On the other hand, it is expected that CUR will easily encapsulated or 
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adsorbed on the water-insoluble SFPs or CMSPs due to the strong hydrophobic interaction 
between hydrophobic CUR and the water-insoluble silk-II structure formed during the salting-out 
process. High encapsulation and loading efficiency of CUR in SFPs and CMSPs are also 
expectable, which is desired for a drug delivery system. Therefore, in this paper, we prepared 
CMSPs with the salting-out method using sodium phosphate instead of potassium phosphate to 
prepare smaller SFPs. The particle properties including size, zeta potential and CUR loading/ 
release efficiency were investigated. In addition, how processing parameters such as pH value of 
sodium phosphate solution affect those properties were also studied. The cytotoxicity and cellular 
uptake performance of CMSPs was investigated using MDA-MB-231 (human breast 
adenocarcinoma) cells. 
 
2. Materials and methods 
2.1. Materials 
Bombyx mori silk was obtained from Jiangsu, R.P. China. Na2CO3 (11552) was purchased from Alfa 
Aesar. Curcumin (C8069) was purchased from LKT Laboratories. Paraformaldehyde (sc-253236A) 
was purchased from Chem Cruz®. K2HPO4 (BP363), KH2PO4 (BP362), CaCl2 (C1016), Na2HPO4 
(S7907), NaH2PO4 (S8282), FeCl2 (44939), FeCl3 (44944), ammonium hydroxide (221228) DMSO 
(Dimethyl sulfoxide, D5879) and Rhodamine B isothiocyanate (R1755) were purchased from 
SIGMA-ALDRICH. Roswell Park Memorial Institute (RPMI) 1640 Medium (BE 12-167F), PBS 
(Dulbecco's Phosphate Buffered Saline, BE17-512F), Penicillin 5.000 U/ml-Streptomycin 5.000 
U/ml (DE17-603E), Foetal Bovine Serum (FBS), L-Glutamine (17-605F) were purchased from 
Lonza®. Texas Red®-X Phalloidin (T7471), MTT (M6494) assay DQG '$3, ƍ
6-Diamidino-2-phenylindole dihydrochloride, D1306) were purchased from Thermo Fisher Scientific. 
MDA-MB-231 cells (Human Caucasian Breast Adenocarcinoma cells) were purchased from 
ECACC. Ultra-High Quality (UHQ) water was prepared using PURELAB Classic (ELGA). 
2.2. Preparation of silk fibroin solution 
Silk was boiled in 0.02 M Na2CO3 solution for 30 min before rinsed 3 to 4 times with UHQ water to 
remove sericin. After drying overnight, the degummed fibroin was dissolved in a ternary system 
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(CaCl2/ Ethanol/ water = 1: 2: 8 molar ratio) at 75°C for 3 h before dialysed in a cellulose tube 
(molecular weight cut off 12 kDa) against UHQ water for 3 days to remove the remaining CaCl2. 
Finally, the SF solution was centrifuged twice (10,000 rpm) and filtered with ȝPILOWHUWRUHPRYH
the impurities. The regenerated silk fibroin (RSF) aqueous solution was stored in the refrigerator at 
4 °C. 
2.3. Preparation of magnetic nanoparticles  
In brief, 4 g FeCl3 and 4.5 g FeCl2 were dissolved in 300 ml UHQ water and then the mixture was 
placed in a 500 ml round-bottom flask for 30 min with a nitrogen purge to replace the air in the flask. 
15 ml ammonium hydroxide was then added to the blend with vigorous stirring under nitrogen 
atmosphere at room temperature for 2 h. The MNPs were washed 5 times and collected using 
Neodymium magnets. The particles were dried over night at room temperature and stored for future 
usage. 
2.4. Preparation of silk fibroin particles and magnetic silk fibroin particles  
2.4.1. Silk fibroin particles preparation 
Briefly, SF solutions with different concentrations (0.1 - 12 mg/ml) were added to potassium 
phosphate or sodium phosphate solutions (ionic strength: 1.25 M, pH 8) in a volume ratio of 1:5 
followed by storing the as-prepared mixtures in the refrigerator for 2 h at -20 °C. The resulting 
particles were unfrozen and centrifuged at 20,000 g for 15 min before being re-dispersed and 
washed three times in UHQ water. To investigate the effect of phosphate ionic strength on SF 
particle size, sodium/ potassium phosphate solutions with ionic strength from 0.6 to 2 M were mixed 
with SF solutions (5 mg/ml). The effect of sodium phosphate pH on the secondary structure of SF 
particles was also studied by producing SFPs with sodium phosphate solutions at pH 4, 7 and 9. 
Secondary structures of SFPs were investigated with Fourier transform infrared (FTIR) 
spectroscopy.  
2.4.2. Magnetic silk fibroin particles preparation 
MNPs were dispersed in sodium phosphate (1.25 M, pH 8) solution to reach the concentration of 
0.1 mg/ml. The MNP-salt mixture was then blended with SF (0.5 - 10 mg/ml) solutions to produce 
particles according to the process mentioned in section 2.4.1 and the resulting MSPs were collected 
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using Neodymium magnets. Sodium phosphate solutions with different pH values were also mixed 
with SF solution (5 mg/ml) to investigate the effect of pH on MSP size. 
2.5. Curcumin loaded magnetic silk fibroin particles  
CUR was dissolved in DMSO with a concentration of 100 mg/ml CUR DMSO solution. 1 mg MNPs 
and different amount of CRU DMSO solutions (with CUR weight equal to 10%, 30%, 60% and 90% 
of total SF used) were added to 10 ml sodium phosphate (1.25 M, pH 8) solution. To investigate the 
effect of pH on CMSP size, zeta potential and CUR release rate, sodium phosphate solutions with 
pH value 4, 7, 8 and 9 were used ( while the CUR usage was 10 %). The prepared mixture was then 
blended with 2 ml SF solution (5 mg/ml) and stored at -20 °C for 2h. The CMSPs were then 
unfrozen and the supernatant was analysed to determine residual CUR concentration using UV-Vis 
spectrometry (JENWAY 6715, Bibby Scientific, UK). Standard calibration curves for CUR in sodium 
phosphate and PBS were used. Concentration of particles was determined by weighing dried 
particles from 1 ml solution. Encapsulation and loading efficiencies were determined by equations 
(1) and (2) below: 
)2(%100%)/(
)1(%100%)/(
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2.6. Release of curcumin from curcumin loaded magnetic silk fibroin core-shell 
nanoparticles 
5 mg of drug loaded CMSPs was washed with UHQ water and suspended in 5 ml PBS (pH 7.4) 
before incubated at 37 °C with shaking (200 rpm). The suspensions were centrifuged (10,000 g) 
every 24 h and the supernatants were carefully removed and replaced with fresh PBS. The CUR 
concentrations of these supernatant were analysed using UV-Vis-spectrometry and the percentage 
of cumulative CUR release was plotted as a function of incubation time.  
2.7. Particle characterization 
2.7.1. Dynamic light scattering and Zeta potential analysis 
The size and Zeta potential of SFPs were measured using dynamic light scattering (DLS) 
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(NanoBrook 90 plus Pals Particle size Analyzer, Brookhaven Instrument, NY, USA). A diode laser 
with wavelength of 660 nm was used. The temperature was kept at 18 °C with a circulation bath. 
Refractive indexes of 1.331 for water and 1.540 for particles were employed for the calculation of 
particle size. 
2.7.2. Fourier transform infrared spectroscopy 
Fourier transform infrared spectroscopy (FTIR) analysis was conducted with Fourier Transform 
Infrared Spectrophotometer (IR Prestige-21, Shimadzu, UK). SFPs were washed three times with 
UHQ water and allowed to air dry on the diamond attenuated total reflectance (ATR) attachment 
(ATR apparatus, Pike Technologies, USA) of the spectrophotometer. The range of wave numbers 
was set from 400 to 4000 cm-1 and the spectrum was read using the Happ-Genzel apodisation 
function over 64 scans with a resolution of 4 cm-1. The amide I region (1575 - 1750 cm-1) was 
investigated to determine the secondary structure of SF protein. The spectral processing was 
conducted with the software IR solution provided within the FTIR instrument. 
2.7.3. Atomic Force Microscopy analysis 
Atomic Force Microscopy (AFM) (Dimension Icon with ScanAsyst, Bruker Corporation, U.S.A) was 
used to reveal the size and morphology of the particles. Particle solutions were dropped on mica 
substrates and air dried before putting on the sample stage, SCANASYST-AIR tip were used and 
the data was analysed with NanoScope Analysis 1.5 software. 
2.7.4. Transmission electron microscopy analysis 
Transmission electron microscopy (TEM) images were obtained using a Fei Tecnai BioTWIN 120 
kV instrument. Operating voltage used was 80 kV. Images recorded using a Gatan Orius SC1000B 
bottom mounted digital camera and Gatan Digital Micrograph software. 
2.8. In vitro cytotoxicity assay 
MDA-MB-231 cells were cultured in RPMI medium supplemented with 10 % Foetal Bovine Serum 
(FBS), 1 % Penicillin / Streptomycin and 1 % L-Glutamine at 37 °C and 5 % CO2. The cytotoxicity of 
SFPs, MSPs and CMSPs against MDA-MB-231 cells was investigated by the MTT assay. The cells 
were seeded in 96 - well plates at a density of 5 × 103 cells per well before incubation for 24 h to 
allow cells to attach to the plates. Cells were then incubated with SFPs, MSPs, CMSPs (30 % CUR 
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usage) and free CUR (amount equal to the CUR content in CMSPs) at preselected concentrations 
respectively. After 3 days incubation, 50 ȝORI mg/ml MTT was added to each well and incubated at 
37 °C for 3 h followed by removing the supernatants and adding ȝO 'MSO. A plate reader 
(Thermo Scientific® Multiskan FC) was used to measure the absorbance of each well including 
control wells containing only medium at 540 nm. The relative cell viability was determined by 
comparing the absorbance with control wells.  
2.9. Cellular uptake assays 
SF was labelled with Rhodamine B isothiocyanate (Ex 543 nm, Em 580 nm) before used for the 
fabrication of SFPs, MSPs and CMSPs fabrication. MDA-MB-231 cells were seeded in 6 - well 
plates with 3 × 105 cells per well and incubated overnight at 37 °C and 5 % CO2 before incubation 
with Rhodamine B labelled SFPs, MSPs and CMSPs (30% CUR usage) at particle concentrations 
in medium from 3 -100 ȝg/ml. After 24 h, the cells were harvested with trypsin and washed twice 
with PBS to remove free particles. The intracellular fluorescence of Rhodamine B and CUR was 
determined using a flow cytometer (FACS Calibur, BD Biosciences, USA) to investigate the particle 
and CUR uptake. 
To obtain microscopy images of cellular uptake, MDA-MB-231 cells were incubated on the cover 
slips in 12 - well plates at a concentration of 1× 105 cells per well and incubated with CMSPs (30% 
CUR usage) at 37 °C and 5 % CO2 for 3 h. Cells were washed three times with PBS to remove 
non-specifically adsorbed particles or CUR before fixation with 4 % paraformaldehyde at room 
temperature for 30 min. The fixed cHOOVZHUHVWDLQHGZLWKȝl 1% Texas Red®-X Phalloidin (Ex 591 
nm, Em 608 nm) for 1 h and washed twice with PBS followed by staining with DAPI (Ex 358 nm, Em 
461 nm) for 30 min. Finally, cells washed twice with PBS ready for fluorescent microscope (AF6000, 
Leica, Germany). Fluorescent images of DAPI, Texas Red and CUR (Ex 340 nm, Em 530 nm 41) 
stained cells were captured using different channels. All images were captured and analyzed with 
LAS AF Lite software (Leica). 
3. Results 
3.1. Controlling the size and secondary structures of silk fibroin nanoparticles 
To investigate the effect of SF concentration and different salts on the size of SFP, SF solution with 
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various concentrations (0.1-12 mg/ml) were added to 1.25 M sodium or potassium phosphate (pH 8) 
solutions and kept at - 20 °C for 2 h. The as-prepared particles were measured with DLS. As shown 
in Fig.1a, when using potassium phosphate, increasing SF concentrations from 0.1 to 12 mg/ml, 
UHVXOWHGLQWKHFKDQJHRISDUWLFOHPHDQGLDPHWHUIURPWRȝPwhich is very similar to the 
result reported by Kaplan and co-workers 37. It is clear that SFPs fabricated with sodium phosphate 
showed much smaller sizes (90 - 300 nm) and narrower size distributions (Fig.1a) than those 
fabricated with potassium phosphate.  
The effect of ionic strength on the size of the particles has also been investigated. Fig.1b illustrates 
the diameter of SFPs fabricated with sodium or potassium phosphate as a function of the ionic 
strength of the salts. Below 0.6 M ionic strength, particles in both salt solutions can hardly be 
detected. Therefore, it was assumed that the lowest ionic strength to form particles is 0.6 M. This 
finding is consistent with the literature 37. Increased ionic strength resulted in larger particles for both 
cases, which is assumed to be a result of enhanced denaturation of SF and aggregation of smaller 
SFPs. It is also clear that at the same ionic strength, particles fabricated with potassium phosphate 
are much larger than those fabricated with sodium phosphate. AFM images of SFPs fabricated by 
adding SF solution (12 mg/ml) into sodium or potassium phosphate solution (1.25 M, pH 8) are 
shown in Fig.1c-d. Particles formed using sodium phosphate are much smaller (380 nm) and 
smoother, while particles formed by potassium phosphate are larger (1800 nm) in size and have a 
rough surface that may result from the aggregation of smaller particles. Therefore, by using different 
phosphate solutions or adjusting their ionic strength, SFPs with a large range of diameters (90 nm- 
ȝPFDQEHSUHSDUHGSURYLGing more options on designing SFPs for different applications. 
The solution pH can also affect particle size. Fig.1e showed the diameter of SFPs fabricated with 
sodium phosphate as a function of pH, the ionic strength of solutions was fixed at 1.25 M. From pH 
4 to 9, the size of particles decreased gradually. The isoelectric point (pI) of SF is 4.53 37, at which 
pH the net charge of SF is close to 0 and thus tend to aggregate due to the increased 
inter-molecular interaction 37. At pH higher than the pI, the net charges of SF are negative and the 
charge density tends to increase as pH increases. As a result, the increased repulsion resulted in 
smaller SFPs and prevented further aggregation. 
To investigate the effect of pH values on SF secondary structures, FTIR analysis was carried out 
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and the results are shown in Fig.1f. Absorption band in the frequency range of 1616 - 1637 cm-1 
UHSUHVHQWVWKHȕ-sheet rich silk-II form while those in the frequency range from 1636 - 1655 cm-1 
represent the random coil rich silk-I form 42. The secondary structure contains more silk II structure, 
and is more hydrophobic, at pH 4 compared to a less hydrophobic silk I-rich structure at pH 9. 
These results explain the change on SFPs size at different pH values: more hydrophobic particles 
have larger tendency to gather and form bigger aggregates. Furthermore, this phenomenon is very 
useful in manipulating drug loading, for example, increasing the loading efficiency of hydrophobic 
drugs on particles by using more hydrophobic particles. 
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Fig.1. Effects of SF concentration, salt, ionic strength and solution pH to the particle size and 
protein secondary structure. a) Particle diameter as a function of SF concentration when adding SF 
solutions (concentration from 0.1-12 mg/ml) to sodium phosphate (Na-P) and potassium phosphate 
(K-P) solutions (both at ionic strength 1.25 M, pH 8) at the volume ratio of 1:5. b) Diameter of SFPs 
fabricated with K-P or Na-P as a function of their ionic strength. The SF concentration was fixed at 5 
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mg/ml. c-d) AFM images of particles fabricated by adding SF solution (12 mg/ml) in to sodium 
phosphate (c) and potassium phosphate (d). Both solutions are at the ionic strength of 1.25 M and 
pH 8. e) Diameter of SFPs fabricated with Na-P as a function of the pH of Na-P solutions. f) FTIR 
spectra of particles produced by salting-out by 1.25 M sodium phosphate at different pH values. The 
results are shown in PHDQ6'Q3. It was found from the above results that the use of sodium 
phosphate, lower ionic strength and higher pH of solution produces smaller SFPs. 
 
3.2. Controlling the size and Zeta potential of magnetic silk fibroin nanoparticles and  
curcumin loaded magnetic silk fibroin core-shell nanoparticles 
Magnetic Fe3O4 nanoparticles (MNPs) with diameter 10 - 30 nm were introduced to SFPs by adding 
MNPs into sodium phosphate solutions (1.25 M, pH 8) before mixed with SF solutions. As shown in 
Fig.2, as-prepared magnetic-SF core-shell particles (MSPs) can be rapidly collected with the help of 
an external magnetic force from a Neodymium magnet, which can be potentially used for the 
targeted delivery of particles to desired tissue sites 40. 
 
 
 
 
 
 
 
Fig.2. MSPs can be rapidly collected with a Neodymium magnet (pull force 25Kg, 25.4mm Diameter 
x 30 mm Thick) within 3 min. 
 
The size of as-prepared MSPs can be manipulated by changing SF concentration or pH values of 
sodium phosphate used. Fig.3a illustrates the diameter of MSPs as a function of SF concentrations. 
The addition of MNPs did not change the particle size of SFPs. Instead, the particles size remained 
 
15 s 30 s 3 min 0 s 
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within the range of 100 - 250 nm. This result is in agreement with the work of Tian et al. who have 
reported that, when using potassium phosphate, the addition of MNPs can dramatically decrease 
the particle size of SFPs from 1.4 µm to 130 - 210 nm 40. Fig.3b showed the effect of sodium 
phosphate pH on MSP diameter. It is clear that both SF concentration and sodium phosphate pH 
affect MSP size similarly as they affect SF particle size (Fig.1a&e), which suggests the property of 
MSPs is dominated by the SF structures coated on the MNPs.  
CMSPs were fabricated by adding CUR and MNPs into sodium phosphate solution (1.25 M, pH 8) 
followed by adding SF solution (5 mg/ml) into the mixture. As shown in Fig.3c, increasing the 
amount of CUR (with weight equivalent to the percentages of the weight of SF used) resulted in the 
diameter increase of CMSPs, indicating the drug loading into the particles. The Zeta potential of the 
CMSPs with different CUR loading was measured. As shown in Fig.3e, higher CUR usages resulted 
in less charge densities, which lead to weaker repulsive interactions and therefore, larger particles. 
The same reason can also be used to explain the effect of pH value on CMSP size. As shown in 
Fig.3d, CMSP diameter decreases with the increase of sodium phosphate pH value. Meanwhile, 
Fig.3f illustrates that higher pH values correspond to higher charge densities. Thus, we may 
conclude that the property of CMSPs is also dominated by its SF content, therefore, higher pH value 
correspond to higher charge densities and smaller particles. 
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Fig.3. The effects of SF concentration, solution pH, and CUR amount to the particle size and zeta 
potential of MSPs and CMSPs. a) The effect of SF concentrations to the diameter of MSPs 
fabricated by sodium phosphate solutions (ionic strength: 1.25 M, pH 8). b) The effect of sodium 
phosphate solution pH to the diameter of MSPs (SF concentration: 5 mg/ml, sodium phosphate 
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ionic strength: 1.25M). c) & e) The effect of CUR amount to the diameter (c) and Zeta potential (e) of 
CMSPs, which were fabricated by adding different amounts of CUR (with weight equivalent to the 
percentages of SF used) to sodium phosphate solutions before SF solutions (5 mg/ml) and MNPs 
were added to the mixed solution. d) & f) The effect of sodium phosphate solution pH to the 
diameter (d) and Zeta potential (f) of CMSPs (SF concentration: 5 mg/ml, CUR amount: 10 % of SF 
used). 7KHUHVXOWVDUHVKRZQLQPHDQ6'Q4. It was found that the size and Zeta potential of 
MSPs and CMSPs can be controlled by altering the SF concentration, solution pH and the amount 
of CUR used in the fabrication process. 
 
To reveal the morphology of the particles before and after the CUR loading, AFM and TEM 
experiments have been carried out. AFM images of MSPs and CMSPs are shown in Fig.4a & b 
respectively. Spherical particles with a smooth surface were observed for MSPs, very similar to the 
morphology of the SFPs (Fig.1c). The diameter of the particles is around 250 nm, consistent with 
the data measured by DLS in Fig. 3a. In contrast, the surface of CMSPs appears to be rougher, 
indicating the loading of CUR into the particles. Presumably, the loading of CUR into the particles 
makes the particles more hydrophobic, therefore, the particles were dehydrated. Fig.4c & d showed 
the TEM images of MSPs and CMSPs respectively. These images indicate clearly that both MSPs 
and CMSPs are formed by multiple magnetic cores covered by SF or SF/ CUR shells, which is in 
agreement with the work by Tian et al 40. The insets in Fig.4c & d are the enlarged images from the 
red boxes. It can be seen from the enlarged images that the black magnetic cores are surrounded 
by SF shells. A number of smaller core-shell particles (~ 30 nm) aggregate to form a bigger particle 
(~ 250 nm). 
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Fig.4. AFM and TEM images of the MSPs and CMSPs. a) & c) AFM and TEM images of MSPs (SF: 
5 mg/ml, ionic strength of sodium phosphate: 1.25 M, pH 8). b) & d) AFM and TEM images of 
CMSPs (SF: 5 mg/ml, ionic strength of sodium phosphate: 1.25 M, pH 8, CUR amount: 10 % of SF 
used). Inserts are the enlarged images of from the red boxes. 
 
3.3. Controlling loading and release of curcumin  
To investigate the loading and release property of MSPs, diverse amounts of CUR were loaded into 
MSPs and the effect of sodium phosphate pH values was also investigated. Fig.5a illustrates the 
effect of CUR amount on encapsulation of CUR. The pH of sodium phosphate solution was fixed at 
8 in this experiment. It can be seen that more than 97 % of CUR has been loaded into MSPs 
regardless of the amount of CUR used. Loading efficiency of CUR into these particles increased 
from ~ 10 % to ~ 80 % with the increasing amount of CUR used as shown in Fig.5c. The 
b. 
c. 
a. 
d. 
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encapsulation and loading efficiency of CUR in CMSPs is remarkably high given the fact that the 
typical loading efficiency for hydrophobic compound loading in protein nanoparticles is around 5% 
47-51
. To investigate the release profile of the CMSPs with different encapsulation and loading 
efficiencies, 5 mg of each type of particles were dispersed in 5 ml PBS (pH 7.4) and incubated at 
37 °C with shaking (200 rpm, overnight). The CUR concentrations in solution were measured at 
different time scales and the cumulative CUR release curves are shown in Fig.5e. Although CMSPs 
with 10 % CUR loading released more in terms of percentage (12.4 % drug released in 20 days) of 
loaded CUR than others during the releasing period, the total amount of released CUR is still less 
than other (30%, 60% and 90% CUR loaded) particles. The drug release rate for CMSPs with 10 % 
CUR loading stays at a higher slope for the first 14 days and gradually level off, while for other 
particles, the release rates are still at steady slopes. The higher accumulative release rate was due 
to the low CUR loading 57. 
Because the structure of SF particles can be controlled by using salt solution with different pH 
values, we have observed the loading / release profiles of CMSPs prepared at different pH values. 
Fig.5b & d illustrate the encapsulation and loading efficiencies of CUR in MSPs fabricated using 
sodium phosphate solutions with different pH values. It can be seen that MSPs fabricated by 
phosphate solutions with pH 4 - 8 have similar CUR encapsulation (over 97 %) and loading (over 
10.5%) efficiencies, however, those using pH 9 solution showed noticeably less encapsulation 
(76 %) and loading (8.4 %) efficiencies than others.Fig.5f shows the cumulative CUR release of 
CMSPs fabricated using sodium phosphate with different pH values. CMSPs fabricated in pH 4 
have released more CUR than those fabricated at higher pH values.  
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Fig.5. Drug leading and release profiles of the CMSPs. a) & b) Encapsulation efficiency of CMSPs 
fabricated with a) various CUR amounts in terms of the amount of SF used (pH 8) and b) various pH 
(CUR amount: 10 %). c) & d) Loading efficiency of CMSPs fabricated with c) various CUR usage 
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(pH 8) and d) various pH (CUR amount: 10 %). e) & f) Cumulative release of CUR from CMSPs 
fabricated with e) different CUR usage (pH 8) and f) different pH (CUR amount: 10 %). For each 
experiment, SF concentration was fixed at 5 mg/ml, ionic strength of sodium phosphate solution 
was fixed at 1.25 M. The results are shown in mean ± SD, n  3. The statistical significance is 
expressed as ***p < 0.001, **p < 0.01, *p <0.05. 
 
3.4. In vitro cytotoxicity assay 
MTT assay has been conducted to investigate the ability of CMSPs to inhibit growth of 
MDA-MB-231 cells. SFPs and MSPs were used as controls. SFPs, MSPs and CMSPs with 30 % 
CUR were incubated with MDA-MB-231 cells for 3 days before determining the relative cell 
viabilities. Free CURs with amount equal to that encapsulated by CMSPs were also incubated and 
the viabilities were compared with that from CMSPs. As illustrated in Fig.6, cell growth was 
significantly inhibited by either CMSPs or free CUR at higher CUR concentrations. Within the dose 
range from 3 to 100 ȝJPO, CMSPs were significantly more cytotoxic to MDA-MB-231 cells than free 
CUR at equivalent CUR dosage. For instance, the cell viability of MDA-MB-231 cells treated with 60 
ȝJPO CMSPs for 3 days was 12.2 ± 6.3 % and when treated with equivalent CUR, the viability was 
46.3 ± 5.2 %, which suggests the inhibition of cancer cell growth was enhanced by CMSPs.  
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Fig.6. In vitro cytotoxicity studies for MDA-MB-231 cells treated with SFPs, MSPs, CMSPs (CUR 
usage: 30 %) and free CUR (amount equivalent to the CUR loaded in CMSPs) for 3 days. Added 
inhibitions of free CUR and MSPs equivalent to the amount of CUR and MSPs in CMSPs were also 
compared (CUR + MSPs). The results are shown in mean ± SD, n = 8. The statistical significance is 
expressed as ***p < 0.001, **p < 0.01, *p <0.05. 
 
To investigate whether the higher cytotoxicity of CMSPs on MDA-MB-231 cells is a simple addition 
of CUR and MSPs cytotoxicity or enhanced CUR delivery by the nanoparticles, the growth inhibition 
result of CMSPs is compared with the added inhibition of corresponding free CUR and MSPs with 
amounts equal to the amounts of CUR and MSP content in CMSPs. The results shown in Fig.6 
demonstrate that CMSPs have higher cytotoxicity than the added toxicities of free CUR and MSPs 
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3.5. Cellular uptake assays 
To investigate the internalization and intracellular drug release behaviours of CMSPs, MDA-MB-231 
cells were treated with different concentrations of CMSPs (with 30 % CUR loaded) and free CUR. 
The amount of free CUR was equal to the CUR content in CMSPs. The percentage of cell uptake of 
CUR is determined by flow cytometry and the results are shown in Fig.7a. The uptake efficiency of 
CUR for cells treated with CMSPs is significantly higher than those treated with free CUR at all 
concentrations and the difference is especially large at lower concentration. This result suggests 
that the enhanced growth inhibition effect of CMSPs, as illustrated in section 3.4, is a result from 
higher CMSPs uptake.  
To investigate whether the uptake efficiency of CMSPs is significantly affected by the CUR content, 
MDA-MB-231 cells were incubated with  SFPs, MSPs and CMSPs (30 % CUR loaded) for 24 h. 
The SF content of these particles was labelled with Rhodamine B which can be detected by flow 
cytometry to determine the uptake of these particles. These results are shown in Fig.7b. All three 
kind of particles displayed similar cellular uptake efficiency and uptake increased with the 
increasing particle concentration. Considerably high uptake efficiency (nearly 70 %) can be reached 
at lower concentration (e.g.10 ȝJPO which is beneficial to drug delivery.  
 
 
 
 
 
 
 
 
Fig.7. Cellular uptake assays of the different particles. a) CUR uptake in MDA-MB-231 cells after 
treated with CMSPs (with 30 % CUR loaded) and equivalent amount of free CUR for 24 h. b) 
Particle uptake efficiency of SFPs, MSPs and CMSPs in MDA-MB-231 cells after incubation for 24 h. 
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SF content in these particles was labelled with Rhodamine B and the uptake efficiencies were 
determined by measuring the cell population containing Rhodamine B fluorescence with flow 
cytometry. The results are shown in mean ± SD, n = 3. The statistical significance is expressed as 
***p < 0.001, **p < 0.01, *p <0.05. It was found that cells treated with CMSPs had significantly 
higher uptake efficiency of CUR than those treated with free CUR. 
 
Fig.8 shows the fluorescent microscopic images of CUR uptake by MDA-MB-231 cells after 
incubation with free CUR (Fig.8a & b) or CMSPs (Fig.8c & d). CUR molecule is auto-fluorescent (Ex 
340 nm, Em 530 nm 41) and was observed with GFP channel. The nucleus and cytoskeleton were 
stained with DAPI and Texas Red®-X Phalloidin. The enhanced CUR uptake effect of CMSPs is 
confirmed by these images. As shown in Fig.8a & b, the green fluorescence in cells that have been 
treated the free CUR, is very weak which suggests the uptake efficiency of free CUR is low, 
consistent with uptake efficiency shown in Fig.7a. In contrast, Fig.8c & d shows that over 90 % of 
the cells incubated with CMSPs have displayed much brighter green fluorescence which appears to 
be quite uniformly distributed within the cytosol. The dramatically increased fluorescence intensity 
suggests that CMSPs can significantly enhance the uptake of CUR for MDA-MB-231 cells. The 
yellow fluorescence in the merged images indicates the co-localization of the Texas red and CUR 
fluorescence. 
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Fig.8. Representative microscopic images of MDA-MB-231 cells incubated with free CUR (a & b, 
CUR amount (10 ȝJPO) equivalent to the CUR loaded in CMSPs (30%)) and CMSPs (c & d, 30 
ȝJPl) for 4 h. Cell nucleus and cytoskeleton were stained with DAPI (blue) and Texas red (red); all 
images were taken with AF6000 microscope (Leica). Comparing the images in a & b to c & d, it can 
be seen that CMSPs significantly improve the cellular uptake of the CUR. 
 
To demonstrate the uptake of the nanoparticles, Fig.9 shows the fluorescent microscopic images of 
FITC-labelled SFPs (Fig.9a & b) and MSPs (Fig.9c & d) uptake by MDA-MB-231 cells. It can be 
seen from Fig.9a & c that over 90 % of the cells have green fluorescence, consistent with uptake 
efficiency shown in Fig.7b. Fig.9b & d shows the uptake by single cells.  
DAPI CUR Merge Texas red 
a. 
b. 
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Fig.9. Representative microscopic images of MDA-MB-231 cells incubated with FITC-labelled SFPs 
(D	EȝJml) or FITC labelled MSPs (F	GȝJPO Cell nucleus and cytoskeleton were 
stained with DAPI (blue) and Texas red (red); all images were taken with AF6000 microscope 
(Leica).  
4. Discussion 
Desolvation and salting-out are two common methods for the fabrication of SF particles 43. While 
the desolvation method 44 is capable of making relatively smaller SFPs (< 200 nm), toxic organic 
solvents such as ethanol, methanol or acetone have to be introduced in the process, which may 
increase the toxicity to cells. On the other hand, SF particles can be prepared by the salting-out 
method without organic solvents involved. Therefore, we have chosen the salting-out method for 
a
b
c
d
DAPI FITC Merge Texas red 
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the fabrication of SFPs in our experiment. In the process of salting-out, SF protein chains will first 
form micellar-like structures in a salt solution due to the enhancement of hydrophobic interactions. 
The particulate globules will then been formed with the micelles by further hydrophobic interactions 
37
. With the salting-out method reported by Kaplan and co-workers, only larger SFPs (0.62 - 2.12 
ȝP) can be produced. However, the sizes of the particles are bigger than the desired size for drug 
delivery. For example, it has been reported that nanoparticles in the range of 100 - 200 nm can 
extravasate through vascular fenestrations of tumours and escape filtration by liver and spleen 38. 
Nanoparticles with diameter ~100 nm are long-lasting in circulation, as the size increased to 150 nm 
and larger, more and more nanoparticles become entrapped in the liver and spleen 38. Therefore, it 
is likely that lots of these SF nanoparticles SFPs with diameters over 600 nm will be filtered by the 
liver and spleen instead of reaching the tumour site once injected into human body. In contrast, 
those fabricated with sodium phosphate showed much smaller sizes (90 - 300 nm) and narrower 
size distributions (Fig.1a). Therefore, it provides a method to prepare SFPs with more appropriate 
sizes for drug delivery without involving organic solvent. The explanation for the difference in 
nanoparticle size created using sodium phosphate and potassium phosphate is to be found in the 
difference in size of the cations (Hofmeister effect). Sodium is relatively small and has a higher 
charge density than the larger potassium ion. The cations will be interacting directly but weakly with 
the partial charges on the neutral SF. The cations strongest effect is likely to be indirect through the 
cations interactions with water or through the interaction of the cation with the phosphate anion. For 
a self-assembly reaction involving multiple intermolecular beta-pleated sheet interactions involved 
in SFP formation there will be an initial dimerization with a high activation energy followed by 
multiple subsequent additions of fibroin monomers with a lower activation energy. The presence of 
the higher charge density cation has reduced the activation energy of the initial dimer formation 
resulting in greater nucleation and numerous small SFPs. Why this happens is subject to conjecture. 
Phosphate is known to indirectly drive protein self-association through competition for water 45 and 
a phenomenological theory is that low charge density ions like potassium negate the effect of the 
high charge density phosphate 46, in this case resulting in fewer larger SFPs. 
The results also showed that the diameter of SFPs, MSPs and CMSPs decrease with the increase 
of sodium phosphate pH value witch suggests that the property of MSPs and CMSPs is dominated 
by their SF content. It can be assumed that when the MSPs or CMSPs were prepared in a pH 9 
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solution, the SF coating became more negatively charged and less hydrophobic, which tend to 
increase the repulsion and decrease the hydrophobic interaction among MSPs or CMSPs and 
eventually fabricate smaller particles. Therefore, the size of MSPs or CMSPs can be controlled by 
altering the pH value of salt solution used in the process. 
Our results revealed that remarkably high encapsulation (>97 %) and loading (10% - 80%) 
efficiency of CUR can be achieved in the CMSPs fabrication process, while typical loading 
efficiency for hydrophobic compound loading in protein nanoparticles is around 5%47-51.This 
phenomenon could owe to the strong hydrophobic interaction between hydrophobic CUR and the 
water-insoluble silk-II structure formed during the salting-out process. Our results have shown 
significant improvement in loading efficiency (up to 80%) compared with 6% found for CUR-loading 
into SF/poly(L-lactic acid-co-e-caprolactone) (P(LLA-CL)) nanofibrous scaffolds 52, 12% for the 
silk/CUR nanoparticles fabricated in supercritical CO2 53, 15% for the SFPs reported by Li et al. 54, 
30% for the silk/CUR nanoparticles produced by desolvation method 55, as well as 10% loading 
efficiency for the paclitaxel loaded SFPs 56. The lower loading efficiency in SFPs via desolvation 
method was due to the fact that CUR tend to dissolve in organic solvent instead of adsorb on SF 
nanoparticles SFPs. However, for loading via slating-out method, the hydrophobic CUR was either 
encapsulated in or adsorbed on the water-insoluble SFPs instead of suspend in the aqueous 
solution. Therefore, the loading of CUR in SFPs via salting-out method is more suitable for the 
fabrication of high CUR-loading SFPs, which is desired for the drug delivery systems. 
Another desired capability of a drug carrier is to be able to control the release of drug and normally 
a longer releasing period is desired. It should be noted that our release profile last 20 days with up 
to 12% release of the CUR which is significant better than the literature which normally last only one 
week 53-55. During the whole period of CUR releasing, the release was progressive without obvious 
burst release, which indicates that the CUR was homogeneously dispersed in the CMSPs. This 
release profile was also in agreement with the work by Xie et al. 53 that the inconspicuous burst 
release was due to the poor water-solubility of CUR. The release profile of CUR from SF matrix can 
be described as a three-step process; firstly, the initial diffusion resulted from desorption of CUR 
from the particle surface, then water penetrates into the matrix and the inner drugs are released. 
Finally, the degradation of SF releases the remaining encapsulated drug 58. Since the burst release 
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of CUR is limited by its poor solubility, the CUR release can be assumed that depend on the 
solubility, diffusion and biodegradation of the SF matrix. It has been reported that the change of SF 
structure can lead to a different release profile of CUR 59. Xie et al. 53 found that silk I structure of SF 
nanofibrous become more water-insoluble when exposed to ethanol vapour, and the ethanol vapour 
treated SF carriers showed a lower CUR release rate than the no-treated ones. Li et al. 54 have 
prepared CUR loaded SFPs by desolvation method, the resulted SF carriers have released only ~ 
5 % of loaded CUR and nearly stopped releasing after 3 days. This low CUR release amount and 
short release period can be explained by the fact that water-LQVROXEOH ȕ-sheet structures were 
formed after the SF have been treated with ethanol 44, thus the hydrophobic CUR tend to remain in 
hydrophobic SF matrix,   
It has been observed that the loading / release profiles of CMSPs can be controlled by the pH value 
of salt solution used. For instance CMSPs fabricated using pH 9 salt solution showed noticeably 
less encapsulation and loading efficiency and also released fewer CUR. On the other hand, CMSPs 
fabricated using pH 4 salt solution have released more CUR than those fabricated at higher pH 
values. Considering the results shown in Fig.1f that MSPs fabricated with pH 9 sodium phosphate 
solutions have more silk-I content than those fabricated in lower pH values, we suspect that the 
secondary structure of SF significantly affects the ability of MSPs in absorbing CUR and the less 
hydrophobic silk-I content is less capable of capturing CUR. For CMSPs fabricated at pH 4, the 
CUR loading was carried out at pH 4 while SF was more hydrophobic and the release was carried 
out at pH 7.4, at which pH the SF become less hydrophobic therefore facilitate the release of the 
hydrophobic CUR. Therefore, the release of CUR depends on the charge and structure of SF which 
can be controlled during the salting-out process. These results suggest that CMSPs possess many 
desired properties such as high encapsulation / loading efficiency and controllable release profile, 
which makes it a promising system for drug delivery.The results also revealed that the inhibition of 
cancer cell growth by CUR was enhanced by CMSPs. 
The enhanced toxicity of CMSPs could be the result of enhanced uptake of CMSPs by cells and the 
encapsulated CUR was released via diffusion or the degradation 53 of SF matrix inside the cells, 
which in turn increased the up take efficiency of CUR, thus decreased the cell viability. SFPs and 
MSPs, on the other hand, had very little effect on cell toxicity at lower concentration and relatively 
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low cytotoxicity at higher concentrations, indicating that SF nanoparticles SFPs and MSP are 
non-toxic nanoparticles. Similar studies have been reported and indicated that SF particles also 
showed no cytotoxicity to many other cell lines 31, 40, 56, 59. For example, Xie et al. 59 have compared 
the in vitro anti-cancer effect of CUR and CUR loaded SF nanoparticles SFPs against HCT-116 
cancer cells. It was found that the CUR-SF nanofibrous matrix had equivalent anti-cancer effect to 
the DMSO dissolved CUR. 
The enhanced cellular uptake of CUR by CMSPs has also been observed in the results, Since CUR 
is a highly hydrophobic drug, its dispersion and diffusion in aqueous solution is significantly poor. 
However, when loaded in CMSPs, CUR was encapsulated within CMSPs and can cross the cell 
membrane for cell uptake. The results are consistent with the reports that SF particles can be taken 
up rapidly by cells 31-32. 
 
Conclusions 
Smaller particles as drug carriers are desired for drug delivery systems. However, SF particles 
fabricated using potassium phosphate are relatively larger (500 -1200 nm). In this paper, we 
developed a method to fabricate SFPs using sodium phosphate and the results indicated that SFPs 
fabricated with sodium phosphate possess significantly smaller size compared with those fabricated 
using potassium phosphate. This new method provides a simple process allowing us to fabricate 
smaller SFPs without using any solvent. Size and secondary structure of SFPs can be controlled by 
changing SF concentration, the pH and ionic strength of sodium phosphate solutions. The size, zeta 
potential and drug loading/releasing efficiency of CMSPs can be controlled by using different SF 
concentrations, CUR amounts and pH values of sodium phosphate solutions. Sustained release of 
CUR from CMSPs was observed for 20 days and CMSPs fabricated at lower pH values showed 
higher CUR release rate. Enhanced growth inhibition of CMSPs against MDA-MB-231 cells was 
observed in MTT assay and CUR uptake efficiency was also significantly enhanced due to the 
better internalization of CMSPs. The effect of particle concentration on cellular uptake efficiency 
was investigated and the results indicate that uptake efficiency can be increased by increasing 
particle concentration. In addition, these particles displayed similar uptake efficiency, which 
suggests the CUR content in CMSPs did not affect the uptake efficiency of particles. Therefore, 
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CMSPs can be used as potential drug delivery system for cancer therapy.  
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AFM image of the magnetic-silk core-shell nanoparticles (left) and fluorescent microscopic 
image (right) of the curcumin delivered human Caucasian breast adenocarcinoma cells.    
 
